1
|
Negri A, Ward C, Bucci A, D'Angelo G, Cauchy P, Radesco A, Ventura AB, Walton DS, Clarke M, Mandriani B, Pappagallo SA, Mondelli P, Liao K, Gargano G, Zaccaria GM, Viggiano L, Lasorsa FM, Ahmed A, Di Molfetta D, Fiermonte G, Cives M, Guarini A, Vegliante MC, Ciavarella S, Frampton J, Volpe G. Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML. Cell Death Dis 2023; 14:763. [PMID: 37996430 PMCID: PMC10667525 DOI: 10.1038/s41419-023-06276-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 10/27/2023] [Accepted: 11/06/2023] [Indexed: 11/25/2023]
Abstract
The transcription factor MYB plays a pivotal role in haematopoietic homoeostasis and its aberrant expression is involved in the genesis and maintenance of acute myeloid leukaemia (AML). We have previously demonstrated that not all AML subtypes display the same dependency on MYB expression and that such variability is dictated by the nature of the driver mutation. However, whether this difference in MYB dependency is a general trend in AML remains to be further elucidated. Here, we investigate the role of MYB in human leukaemia by performing siRNA-mediated knock-down in cell line models of AML with different driver lesions. We show that the characteristic reduction in proliferation and the concomitant induction of myeloid differentiation that is observed in MLL-rearranged and t(8;21) leukaemias upon MYB suppression is not seen in AML cells with a complex karyotype. Transcriptome analyses revealed that MYB ablation produces consensual increase of MAFB expression in MYB-dependent cells and, interestingly, the ectopic expression of MAFB could phenocopy the effect of MYB suppression. Accordingly, in silico stratification analyses of molecular data from AML patients revealed a reciprocal relationship between MYB and MAFB expression, highlighting a novel biological interconnection between these two factors in AML and supporting new rationales of MAFB targeting in MLL-rearranged leukaemias.
Collapse
Affiliation(s)
- A Negri
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - C Ward
- Edge Impulse Inc., San Jose, CA, USA
| | - A Bucci
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - G D'Angelo
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - P Cauchy
- Max Planck Institute of Immunobiology and Epigenetics, 79108, Freiburg, Germany
| | - A Radesco
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - A B Ventura
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - D S Walton
- Clent Life Sciences, DY84HD, Stourbridge, UK
| | - M Clarke
- Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, B152TT, Birmingham, UK
| | - B Mandriani
- Department of Bioscience, Biotechnology and Environment, University of Bari "Aldo Moro", 70125, Bari, Italy
| | - S A Pappagallo
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - P Mondelli
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - K Liao
- School of Biology and Biological Engineering, South China University of Technology, Guangzhou, 510006, China
| | - G Gargano
- Department of Mathematics, University of Bari "Aldo Moro", Bari, Italy
| | - G M Zaccaria
- Department of Electrical and Information Engineering, Polytechnic University of Bari, Bari, Italy
| | - L Viggiano
- Department of Biology, University of Bari "Aldo Moro", Bari, Italy
| | - F M Lasorsa
- Department of Bioscience, Biotechnology and Environment, University of Bari "Aldo Moro", 70125, Bari, Italy
| | - A Ahmed
- Department of Bioscience, Biotechnology and Environment, University of Bari "Aldo Moro", 70125, Bari, Italy
| | - D Di Molfetta
- Department of Bioscience, Biotechnology and Environment, University of Bari "Aldo Moro", 70125, Bari, Italy
| | - G Fiermonte
- Department of Bioscience, Biotechnology and Environment, University of Bari "Aldo Moro", 70125, Bari, Italy
| | - M Cives
- Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Bari, Italy
| | - A Guarini
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - M C Vegliante
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - S Ciavarella
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
| | - J Frampton
- Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, B152TT, Birmingham, UK.
| | - G Volpe
- Hematology and Cell Therapy Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
| |
Collapse
|
2
|
Mele A, Prete E, Citiso S, Mele G, Pastore D, Sgherza N, Curci P, Musto P, Falcone AP, Cascavilla N, Germano C, Giuseppe T, Reddiconto G, Di Renzo N, Palazzo G, Mazza P, Rossini B, Guarini A, Palumbo G, Melillo LMA, Pavone V. PB2016: COMPARISON BETWEEN DRD VS KRD AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS IN FIRST RELAPSE: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP). Hemasphere 2022. [PMCID: PMC9431550 DOI: 10.1097/01.hs9.0000850896.11254.d1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
3
|
Mele G, Cascavilla N, Di Renzo N, Guarini A, Mazza P, Melillo L, Pavone V, Tarantini G, Curci P, Falcone AP, Germano C, Mele A, Palazzo G, Palumbo G, Reddiconto G, Rossini B, Specchia G, Musto P, Pastore D. Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'. Ann Hematol 2022; 101:1727-1739. [PMID: 35587825 DOI: 10.1007/s00277-022-04857-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2022] [Accepted: 04/24/2022] [Indexed: 12/01/2022]
Abstract
We report herein a multicentre retrospective analysis of 192 consecutive patients with symptomatic refractory/relapsed multiple myeloma (RRMM) treated with daratumumab in combination with bortezomib or lenalidomide as salvage therapy at 9 haematological centres in Puglia. Choice of both regimens was based on previous treatment and/or physicians' preference. Considering the under-representation of older patients (very old patient ≥ 80 years) in clinical trials and the prognostic and predictive importance and value of frailty status, here, we further characterised the patient cohort by age. The overall response rate (ORR) was generally lower than what was previously reported in the CASTOR (ORR 72.6% vs 85%) and POLLUX (ORR 86.5% vs 93%) trials. The lower ORR in our analysis compared to the CASTOR and POLLUX trials could be related to a less selected population. Similarly, amongst very old patients, the ORR was encouraging: ORR to treatment with DVd (daratumumab + bortezomib + dexamethasone) was 66.7%, and ORR to treatment with DRd (daratumumab + lenalidomide + dexamethasone) was 92.3%. Median TTP (time to progression) was 10.8 months (1-year TTP: 44.7%; 2-year TTP: 25.3%) in the DVd group; median TTP was not reached in the DRd group (1-year TTP: 82.7%; 2-year TTP: 71.4%). Median OS (overall survival) was not reached either in the DRd group (1-year OS: 85.9%; 2-year OS: 73.7%) or the DVd group (1-year OS: 70.2%; 2-year OS: 58.9%).
Collapse
Affiliation(s)
- G Mele
- Haematology and BMT Unit, Ospedale A. Perrino, SS 7 per Mesagne, 72100, Brindisi, Italy.
| | - N Cascavilla
- Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - N Di Renzo
- Haematology, Ospedale V. Fazzi, Lecce, Italy
| | - A Guarini
- Haematology, Ospedale Giovanni Paolo II°, Bari, Italy
| | - P Mazza
- Haematology, Ospedale G. Moscati, Taranto, Italy
| | - L Melillo
- Haematology, Ospedali Riuniti, Foggia, Italy
| | - V Pavone
- Haematology, Ospedale Cardinale Panico, Tricase, Lecce, Italy
| | - G Tarantini
- Haematology, Ospedale Monsignor R. Dimiccoli, Barletta, Bari, Italy
| | - P Curci
- University of Bari Medical School, Policlinico, Bari, Italy
| | - A P Falcone
- Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy
| | - C Germano
- Haematology, Ospedale Monsignor R. Dimiccoli, Barletta, Bari, Italy
| | - A Mele
- Haematology, Ospedale Cardinale Panico, Tricase, Lecce, Italy
| | - G Palazzo
- Haematology, Ospedale G. Moscati, Taranto, Italy
| | - G Palumbo
- Haematology, Ospedali Riuniti, Foggia, Italy
| | | | - B Rossini
- Haematology, Ospedale Giovanni Paolo II°, Bari, Italy
| | - G Specchia
- University of Bari Medical School, Policlinico, Bari, Italy
| | - P Musto
- University of Bari Medical School, Policlinico, Bari, Italy
| | - D Pastore
- Haematology and BMT Unit, Ospedale A. Perrino, SS 7 per Mesagne, 72100, Brindisi, Italy
| |
Collapse
|
4
|
Minoia C, Gerardi C, Allocati E, De Sanctis V, Franceschetti S, Viviani S, Annunziata MA, Bari A, Skrypets T, Oliva S, Puzzovivo A, Di Molfetta S, Caccavari V, Di Russo A, Loseto G, Daniele A, Nassi L, Gini G, Guarini A. LATE TOXICITIES AND LONG‐TERM MONITORING IN CLASSICAL HODGKIN LYMPHOMA AND DIFFUSE LARGE B‐CELL LYMPHOMA SURVIVORS: A SERIES OF SYSTEMATIC REVIEWS OF THE FONDAZIONE ITALIANA LINFOMI. Hematol Oncol 2021. [DOI: 10.1002/hon.105_2881] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- C. Minoia
- IRCCS Istituto Tumori "Giovanni Paolo II" Hematology Unit Bari Italy
| | - C. Gerardi
- Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS Centro Politiche Regolatorie in Sanità Milan Italy
| | - E. Allocati
- Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS Centro Politiche Regolatorie in Sanità Milan Italy
| | - V. De Sanctis
- Faculty of Medicina e Psicologia Sant'Andrea Hospital University of Rome "La Sapienza" Department of Radiation Oncology Rome Italy
| | | | - S. Viviani
- IEO European Institute of Oncology IRCCS Division of Hemato‐Oncology Milan Italy
| | - M. A. Annunziata
- Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Unit of Oncological Psychology Aviano Italy
| | - A. Bari
- Università di Modena e Reggio Emilia UO Terapie Mirate in Oncoematologia ed Osteoncologia Dipartimento di Scienze Mediche e Chirurgiche Materno‐Infantili e dell'Adulto Modena Italy
| | - T. Skrypets
- IRCCS Istituto Tumori "Giovanni Paolo II" Hematology Unit Bari Italy
| | - S. Oliva
- IRCCS Istituto Tumori "Giovanni Paolo II" Cardiology Unit Bari Italy
| | - A. Puzzovivo
- IRCCS Istituto Tumori "Giovanni Paolo II Cardiology Unit Bari Italy
| | - S. Di Molfetta
- University of Bari "Aldo Moro" Department of Emergency and Organ Transplantation Section of Internal Medicine Endocrinology Andrology and Metabolic Diseases Bari Italy
| | - V. Caccavari
- Istituto Clinico Città Studi Assisted Reproduction Unit Milan Italy
| | - A. Di Russo
- Fondazione IRCCS Istituto Nazionale dei Tumori Radiotherapy Unit Milan Italy
| | - G. Loseto
- IRCCS Istituto Tumori "Giovanni Paolo II" Hematology Unit Bari Italy
| | - A. Daniele
- IRCCS Istituto Tumori "Giovanni Paolo II" Experimental Oncology and Biobank Management Unit Bari Italy
| | - L. Nassi
- Careggi Hospital and University of Florence Lymphoma Unit Hematology Department Florence Italy
| | - G. Gini
- AOU Ospedali Riuniti Ancona‐Università Politecnica delle Marche Clinic of Hematology Ancona Italy
| | - A. Guarini
- IRCCS Istituto Tumori "Giovanni Paolo II" Hematology Unit Bari Italy
| |
Collapse
|
5
|
Pulsoni A, Tosti ME, Ferrero S, Luminari S, Dondi A, Liberati AM, Cenfra N, Renzi D, Zanni M, Boccomini C, Ferreri AJ, Rattotti S, Zilioli VR, Bernuzzi P, Bolis S, Musuraca G, Nassi L, Perrone T, Stelitano C, Anastasia A, Corradini P, Partesotti G, Re F, Cencini E, Mannarella C, Mannina D, Molinari AL, Tani M, Annechini G, Assanto GM, Grapulin L, Guarini A, Cavalli M, De Novi LA, Ciabatti E, Mantoan B, Della Starza I, Arcaini L, Ricardi U, Gattei V, Galimberti S, Ladetto M, Foà R, Del Giudice I. UPDATED RESULTS OF THE FIL “MIRO” STUDY, A MULTICENTER PHASE II TRIAL COMBINING LOCAL RADIOTHERAPY AND MRD‐DRIVEN IMMUNOTHERAPY IN EARLY‐STAGE FOLLICULAR LYMPHOMA. Hematol Oncol 2021. [DOI: 10.1002/hon.31_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- A. Pulsoni
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - M. E. Tosti
- Istituto Superiore di Sanità National Center for Global Health Roma Italy
| | - S. Ferrero
- Hematology Division University of Torino/AOU "Città della Salute e della Scienza di Torino" Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - S. Luminari
- Hematology Unit Arcispedale S. Maria Nuova, Azienda Unità Sanitaria Locale ‐ IRCCS, University of Modena and Reggio Emilia Reggio Emilia Italy
| | - A. Dondi
- Fondazione Italiana Linfomi Onlus, (FIL) Modena Italy
| | - A. M. Liberati
- A.O. Santa Maria Terni, University of Perugia Perugia Italy
| | - N. Cenfra
- Hematology Unit, S. Maria Goretti Hospital AUSL Latina Latina Italy
| | - D. Renzi
- Hematology and Stem Cells Transplantation Unit IRCCS Istituto Nazionale dei Tumori Regina Elena Roma Italy
| | - M. Zanni
- Division of Hematology, SS. Antonio e Biagio Hospital Alessandria Italy
| | - C. Boccomini
- Hematology Department Città della Salute e della Scienza Torino Italy
| | - A. J. Ferreri
- Lymphoma Unit IRCCS San Raffaele Scientific Institute Department of Onco‐Haematology Milano Italy
| | - S. Rattotti
- Division of Hematology Fondazione IRCCS Policlinico San Matteo Pavia Italy
| | - V. R. Zilioli
- Division of Hematology ASST Grande Ospedale Metropolitano Niguarda Milano Italy
| | - P. Bernuzzi
- Hematology Unit, Guglielmo da Saliceto Hospital Department of Onco‐Hematology Piacenza Italy
| | - S. Bolis
- Hematology Department ASST San Gerardo University Hospital Monza Italy
| | - G. Musuraca
- Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori” Meldola (FC) Italy
| | - L. Nassi
- Division of Hematology University of Eastern Piedmont Department of Translational Medicine Novara Italy
| | - T. Perrone
- Unit of Hematology with Transplantation University of Bari, Dept. of Emergency and Organ Transplantation Bari Italy
| | - C. Stelitano
- Department of Haematology Azienda Ospedaliera Bianchi Melacrino Morelli Reggio Calabria Italy
| | - A. Anastasia
- Hematology, ASST Spedali Civili di Brescia Brescia Italy
| | - P. Corradini
- Division of Hematology Fondazione IRCCS Istituto Nazionale dei Tumori di Milano Milano Italy
| | - G. Partesotti
- Onco‐Hematology Department Nuovo ospedale civile of Sassuolo Sassuolo Italy
| | - F. Re
- Hematology Clinic, A.O.U. di Parma Parma Italy
| | - E. Cencini
- Unit of Hematology Azienda Ospedaliera Universitaria Senese & University of Siena Siena Italy
| | - C. Mannarella
- Hematology Unit "Madonna delle Grazie" Hospital Matera Italy
| | - D. Mannina
- Department of Hematology Azienda Ospedaliera Papardo Messina Italy
| | | | - M. Tani
- Hematology Unit Santa Maria delle Croci Hospital Ravenna Italy
| | - G. Annechini
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - G. M. Assanto
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. Grapulin
- Department of Radiotherapy Policlinico Umberto I, Sapienza University Roma Italy
| | - A. Guarini
- Hematology, Sapienza University Department of Molecular Medicine Roma Italy
| | - M. Cavalli
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. A. De Novi
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - E. Ciabatti
- Section of Hematology, University of Pisa Department of Clinical and Experimental Medicine Pisa Italy
| | - B. Mantoan
- Hematology Division University of Torino Department of Molecular Biotechnologies and Health Sciences Torino Italy
| | - I. Della Starza
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - L. Arcaini
- Division of Hematology, Fondazione IRCCS Policlinico San Matteo University of Pavia, Department of Molecular Medicine Pavia Italy
| | - U. Ricardi
- Radiation Oncology, University of Turin Department of Oncology Torino Italy
| | - V. Gattei
- Clinical and Experimental Onco‐Hematology Unit CRO Aviano National Cancer Institute Aviano Italy
| | - S. Galimberti
- Section of Hematology University of Pisa, Department of Clinical and Experimental Medicine Pisa Italy
| | - M. Ladetto
- Hematology, Az Ospedaliera Santi Antonio e Biagio e Cesare Arrigo Università del Piemonte Orientale Alessandria Italy
| | - R. Foà
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| | - I. Del Giudice
- Hematology, Sapienza University Department of Translational and Precision Medicine Roma Italy
| |
Collapse
|
6
|
Catino A, Bafunno D, Cormio C, Romito F, Minoia C, Loseto G, Dellino M, Opinto G, Silvestris E, Guarini A, Giotta F, Latorre A, Montrone M, Pizzutilo P, Longo V, Mastrandrea A, Ricci D, Pesola F, Galetta D. FP06.04 Psychological Distress in Outpatients with Lymphoma, Lung and Breast Cancer during COVID-19 pandemic. J Thorac Oncol 2021. [PMCID: PMC7976877 DOI: 10.1016/j.jtho.2021.01.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
7
|
Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ann Oncol 2019; 30:2015. [PMID: 31539020 PMCID: PMC6938597 DOI: 10.1093/annonc/mdz386] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- S Ciavarella
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - M C Vegliante
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - M Fabbri
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan
| | - S De Summa
- Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - F Melle
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan
| | - G Motta
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan
| | - V De Iuliis
- Post-graduated Medical School of Clinical Pathology, "Gabriele D'Annunzio", University of Chieti, Chieti
| | - G Opinto
- Functional Biomorphology Laboratory, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A Enjuanes
- Unitat de Genòmica, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona; CIBERONC, Barcelona, Spain
| | - S Rega
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - A Gulino
- Tumor Immunology Unit, Dipartimento per la Promozione della Salute e Materno Infantile "G. D'Alessandro", University of Palermo, Palermo
| | - C Agostinelli
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna
| | - A Scattone
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - S Tommasi
- Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - A Mangia
- Functional Biomorphology Laboratory, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - F Mele
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - G Simone
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - A F Zito
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - G Ingravallo
- Pathology Section, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", Bari
| | - U Vitolo
- Department of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino
| | - A Chiappella
- Department of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino
| | - C Tarella
- Onco-Hematology Unit, European Institute of Oncology, IRCCS, Milan
| | - A M Gianni
- Onco-Hematology Unit, European Institute of Oncology, IRCCS, Milan
| | - A Rambaldi
- Department of Hematology and Oncology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo; School of Medicine, University of Milan, Milan, Italy
| | - P L Zinzani
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna
| | - B Casadei
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna
| | - E Derenzini
- Onco-Hematology Unit, European Institute of Oncology, IRCCS, Milan
| | - G Loseto
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - A Pileri
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna
| | - V Tabanelli
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan
| | - S Fiori
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan
| | - A Rivas-Delgado
- CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona; IDIBAPS, Barcelona, Spain
| | - A López-Guillermo
- CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona; IDIBAPS, Barcelona, Spain
| | - T Venesio
- Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy
| | - A Sapino
- Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Italy; Department of Medical Sciences, University of Torino, Turin, Italy
| | - E Campo
- CIBERONC, Barcelona, Spain; Haematopathology Unit, Pathology Department, Hospital Clínic, Barcelona; University of Barcelona, Barcelona, Spain
| | - C Tripodo
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - A Guarini
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari
| | - S A Pileri
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan
| |
Collapse
|
8
|
Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Ann Oncol 2019; 29:2363-2370. [PMID: 30307529 PMCID: PMC6311951 DOI: 10.1093/annonc/mdy450] [Citation(s) in RCA: 73] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Background Gene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL), but the routinely adoption of prognostic stromal signatures remains limited. Patients and methods Here, we applied the computational method CIBERSORT to generate a 1028-gene matrix incorporating signatures of 17 immune and stromal cytotypes. Then, we carried out a deconvolution on publicly available GEP data of 482 untreated DLBCLs to reveal associations between clinical outcomes and proportions of putative tumor-infiltrating cell types. Forty-five genes related to peculiar prognostic cytotypes were selected and their expression digitally quantified by NanoString technology on a validation set of 175 formalin-fixed, paraffin-embedded DLBCLs from two randomized trials. Data from an unsupervised clustering analysis were used to build a model of clustering assignment, whose prognostic value was also assessed on an independent cohort of 40 cases. All tissue samples consisted of pretreatment biopsies of advanced-stage DLBCLs treated by comparable R-CHOP/R-CHOP-like regimens. Results In silico analysis demonstrated that higher proportion of myofibroblasts (MFs), dendritic cells, and CD4+ T cells correlated with better outcomes and the expression of genes in our panel is associated with a risk of overall and progression-free survival. In a multivariate Cox model, the microenvironment genes retained high prognostic performance independently of the cell-of-origin (COO), and integration of the two prognosticators (COO + TME) improved survival prediction in both validation set and independent cohort. Moreover, the major contribution of MF-related genes to the panel and Gene Set Enrichment Analysis suggested a strong influence of extracellular matrix determinants in DLBCL biology. Conclusions Our study identified new prognostic categories of DLBCL, providing an easy-to-apply gene panel that powerfully predicts patients’ survival. Moreover, owing to its relationship with specific stromal and immune components, the panel may acquire a predictive relevance in clinical trials exploring new drugs with known impact on TME.
Collapse
Affiliation(s)
- S Ciavarella
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - M C Vegliante
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - M Fabbri
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan, Italy
| | - S De Summa
- Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - F Melle
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan, Italy
| | - G Motta
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan, Italy
| | - V De Iuliis
- Post-graduated Medical School of Clinical Pathology, "Gabriele D'Annunzio", University of Chieti, Chieti, Italy
| | - G Opinto
- Functional Biomorphology Laboratory, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A Enjuanes
- Unitat de Genòmica, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; CIBERONC, Barcelona, Spain
| | - S Rega
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A Gulino
- Tumor Immunology Unit, Dipartimento per la Promozione della Salute e Materno Infantile "G. D'Alessandro", University of Palermo, Palermo, Italy
| | - C Agostinelli
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna, Italy
| | - A Scattone
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - S Tommasi
- Molecular Diagnostics and Pharmacogenetics Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A Mangia
- Functional Biomorphology Laboratory, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - F Mele
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - G Simone
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A F Zito
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - G Ingravallo
- Pathology Section, Department of Emergency and Organ Transplantation (DETO), University of Bari "Aldo Moro", Bari, Italy
| | - U Vitolo
- Department of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - A Chiappella
- Department of Hematology, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
| | - C Tarella
- Onco-Hematology Unit, European Institute of Oncology, IRCCS, Milan, Italy
| | - A M Gianni
- Onco-Hematology Unit, European Institute of Oncology, IRCCS, Milan, Italy
| | - A Rambaldi
- Department of Hematology and Oncology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII, Bergamo, Italy; School of Medicine, University of Milan, Milan, Italy
| | - P L Zinzani
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna, Italy
| | - B Casadei
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna, Italy
| | - E Derenzini
- Onco-Hematology Unit, European Institute of Oncology, IRCCS, Milan, Italy
| | - G Loseto
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A Pileri
- Department of Experimental, Diagnostic, and Specialty Medicine (DIMES), Bologna University School of Medicine, Bologna, Italy
| | - V Tabanelli
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan, Italy
| | - S Fiori
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan, Italy
| | - A Rivas-Delgado
- CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona, Spain; IDIBAPS, Barcelona, Spain
| | - A López-Guillermo
- CIBERONC, Barcelona, Spain; Hematology Department, Hospital Clínic, Barcelona, Spain; IDIBAPS, Barcelona, Spain
| | - T Venesio
- Pathology Department, Candiolo Cancer Institute, Turin, Italy
| | - A Sapino
- Pathology Department, Candiolo Cancer Institute, Turin, Italy
| | - E Campo
- CIBERONC, Barcelona, Spain; Haematopathology Unit, Pathology Department, Hospital Clínic, Barcelona, Spain; University of Barcelona, Barcelona, Spain
| | - C Tripodo
- Pathology Department, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - A Guarini
- Hematology and Cell Therapy Unit, IRCCS-Istituto Tumori 'Giovanni Paolo II', Bari, Italy
| | - S A Pileri
- Division of Diagnostic Haematopathology, European Institute of Oncology, IRCCS, Milan, Italy.
| |
Collapse
|
9
|
Raponi S, Del Giudice I, Marinelli M, Wang J, Cafforio L, Ilari C, Piciocchi A, Messina M, Bonina S, Tavolaro S, Bordyuh M, Mariglia P, Peragine N, Mauro FR, Chiaretti S, Molica S, Gentile M, Visentin A, Trentin L, Rigolin GM, Cuneo A, Diop F, Rossi D, Gaidano G, Guarini A, Rabadan R, Foà R. Genetic landscape of ultra-stable chronic lymphocytic leukemia patients. Ann Oncol 2019; 29:966-972. [PMID: 29365086 DOI: 10.1093/annonc/mdy021] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background Chronic lymphocytic leukemia (CLL) has a heterogeneous clinical course. Beside patients requiring immediate treatment, others show an initial indolent phase followed by progression and others do not progress for decades. The latter two subgroups usually display mutated IGHV genes and a favorable FISH profile. Patients and methods Patients with absence of disease progression for over 10 years (10-34) from diagnosis were defined as ultra-stable CLL (US-CLL). Forty US-CLL underwent extensive characterization including whole exome sequencing (WES), ultra-deep sequencing and copy number aberration (CNA) analysis to define their unexplored genetic landscape. Microarray analysis, comparing US-CLL with non-US-CLL with similar immunogenetic features (mutated IGHV/favorable FISH), was also carried out to recognize US-CLL at diagnosis. Results WES was carried out in 20 US-CLL and 84 non-silent somatic mutations in 78 genes were found. When re-tested in a validation cohort of 20 further US-CLL, no recurrent lesion was identified. No clonal mutations of NOTCH1, BIRC3, SF3B1 and TP53 were found, including ATM and other potential progression driving mutations. CNA analysis identified 31 lesions, none with known poor prognostic impact. No novel recurrent lesion was identified: most cases showed no lesions (38%) or an isolated del(13q) (31%). The expression of 6 genes, selected from a gene expression profile analysis by microarray and quantified by droplet digital PCR on a cohort of 79 CLL (58 US-CLL and 21 non-US-CLL), allowed to build a decision-tree capable of recognizing at diagnosis US-CLL patients. Conclusions The genetic landscape of US-CLL is characterized by the absence of known unfavorable driver mutations/CNA and of novel recurrent genetic lesions. Among CLL patients with favorable immunogenetics, a decision-tree based on the expression of 6 genes may identify at diagnosis patients who are likely to maintain an indolent disease for decades.
Collapse
Affiliation(s)
- S Raponi
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - I Del Giudice
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - M Marinelli
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - J Wang
- Division of Life Science and Department of Chemical and Biological Engineering, Hong Kong University of Science and Technology, Hong Kong
| | - L Cafforio
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - C Ilari
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - A Piciocchi
- GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy
| | - M Messina
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Bonina
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Tavolaro
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - M Bordyuh
- Department of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA
| | - P Mariglia
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - N Peragine
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - F R Mauro
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Chiaretti
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy
| | - S Molica
- Department of Hematology-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy
| | - M Gentile
- Hematology Uni, Department of Hemato-Oncology, Ospedale Annunziata, Cosenza, Italy
| | - A Visentin
- Hematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
| | - L Trentin
- Hematology Sectio, Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
| | - G M Rigolin
- Hematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - A Cuneo
- Hematology Sectio, Azienda Ospedaliero Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - F Diop
- Division of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - D Rossi
- Department of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland; Institute of Oncology Research, Bellinzona, Switzerland
| | - G Gaidano
- Division of Hematolog, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy
| | - A Guarini
- Department of Molecular Medicine, Sapienza University, Rome, Italy
| | - R Rabadan
- Department of Systems Biology, Columbia University, New York, USA; Department of, Biomedical Informatics, Columbia University, New York, USA
| | - R Foà
- Hematolog, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy.
| |
Collapse
|
10
|
Pileri S, Mazzara S, Derenzini E, Melle F, Motta G, Tabanelli V, Vitolo U, Chiappella A, Fabbri M, Agostinelli C, Tarella C, Rambaldi A, Guarini A, Opinto G, Vegliante M, De Summa S, Ciavarella S. INTEGRATING TUMOR- AND MICROENVIRONMENT-REFLECTING GENES IN A UNIQUE AND ROUTINE-APPLICABLE ASSAY FOR ACCURATE RISK PREDICTION IN DLBCL. Hematol Oncol 2019. [DOI: 10.1002/hon.98_2629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- S.A. Pileri
- Unit of Diagnostic Hematopathology; European Institute of Oncology, IRCCS; Milan Italy
| | - S. Mazzara
- Unit of Diagnostic Hematopathology; European Institute of Oncology, IRCCS; Milan Italy
| | - E. Derenzini
- Onco-Hematology Unit; European Institute of Oncology, IRCCS; Milan Italy
| | - F. Melle
- Unit of Diagnostic Hematopathology; European Institute of Oncology, IRCCS; Milan Italy
| | - G. Motta
- Unit of Diagnostic Hematopathology; European Institute of Oncology, IRCCS; Milan Italy
| | - V. Tabanelli
- Unit of Diagnostic Hematopathology; European Institute of Oncology, IRCCS; Milan Italy
| | - U. Vitolo
- Department of Hematology; Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - A. Chiappella
- Department of Hematology; Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Torino Italy
| | - M. Fabbri
- Unit of Diagnostic Hematopathology; European Institute of Oncology, IRCCS; Milan Italy
| | - C. Agostinelli
- Department of Experimental; Diagnostic and Specialty Medicine (DIMES), Bologna University School of Medicine; Bologna Italy
| | - C. Tarella
- Onco-Hematology Unit; European Institute of Oncology, IRCCS; Milan Italy
| | - A. Rambaldi
- Department of Hematology and Oncology, Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII; Bergamo and University of Milan, School of Medicine; Milan Italy
| | - A. Guarini
- Hematology and Cell Therapy Unit; IRCCS-Istituto Tumori 'Giovanni Paolo II'; Bari Italy
| | - G. Opinto
- Hematology and Cell Therapy Unit; IRCCS-Istituto Tumori 'Giovanni Paolo II'; Bari Italy
| | | | - S. De Summa
- Hematology and Cell Therapy Unit; IRCCS-Istituto Tumori 'Giovanni Paolo II'; Bari Italy
| | | |
Collapse
|
11
|
Porcelli L, Stolfa D, Stefanachi A, Di Fonte R, Garofoli M, Iacobazzi RM, Silvestris N, Guarini A, Cellamare S, Azzariti A. Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimitotic agents for the treatment of Hodgkin Lymphoma. Cancer Lett 2018; 445:1-10. [PMID: 30583077 DOI: 10.1016/j.canlet.2018.12.013] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2018] [Revised: 12/05/2018] [Accepted: 12/11/2018] [Indexed: 12/16/2022]
Abstract
We previously demonstrated that some N-biphenylanilides caused cell-cycle arrest at G2/M transition in breast cancer cells. Among them we choose three derivatives, namely PTA34, PTA73 and RS35 for experimentation in solid tumor cell lines, classical Hodgkin Lymphoma (cHL) cell lines and bona fide normal cell lines. Almost all tumor cells were sensitive to compounds in the nanomolar range whereas, they were not cytotoxic to normal ones. Interestingly the compounds caused a strong G2/M phase arrest in cHL cell lines, thus, here we investigated whether they affected the integrity of microtubules in such cells. We found that they induced a long prometaphase arrest, followed by induction of apoptosis which involved mitochondria. PTA73 and RS35 induced the mitotic arrest through the fragmentation of microtubules which prevented the kinethocore-mitotic spindle interaction and the exit from mitosis. PTA34 is instead a tubulin-targeting agent because it inhibited the tubulin polymerization as vinblastine. As such, PTA34 maintained the Cyclin B1-CDK1 regulatory complex activated during the G2/M arrest while inducing the inactivation of Bcl-2 through phosphorylation in Ser70, the degradation of Mcl-1 and a strong activation of BIML and BIMS proapoptotic isoforms. In addition PTA34 exerted an antiangiogenic effect by suppressing microvascular formation.
Collapse
Affiliation(s)
- L Porcelli
- Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - D Stolfa
- Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy; Dipartimento di Farmacia-Scienza del Farmaco, Università di Bari, Bari, Italy
| | - A Stefanachi
- Dipartimento di Farmacia-Scienza del Farmaco, Università di Bari, Bari, Italy
| | - R Di Fonte
- Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - M Garofoli
- Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - R M Iacobazzi
- Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - N Silvestris
- Medical Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - A Guarini
- Haematology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - S Cellamare
- Dipartimento di Farmacia-Scienza del Farmaco, Università di Bari, Bari, Italy
| | - A Azzariti
- Experimental Pharmacology Laboratory, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy.
| |
Collapse
|
12
|
Pareti FI, Gugliotta L, Mannucci L, Guarini A, Mannucci PM. Biochemical and Metabolic Aspects of Platelet Dysfunction in Chronic Myeloproliferative Disorders. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1657135] [Citation(s) in RCA: 62] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryFifty-two patients with chronic myeloproliferative disorders (13 with polycythemia vera; 23 with primary thrombocythemia; 6 with myelofibrosis and 10 with chronic granulocytic leukemia) had low platelet levels of adenine nucleotides and serotonin and abnormal uptake and storage of the amine. The storage pool deficiency was confined to the substances contained in the platelet dense bodies, because α-granule and lysosome markers were present in normal amounts. In chronic granulocytic leukemia the storage defect was usually less marked but was accompanied by a decreased formation of thromboxane B2 and normal platelet aggregation in response to arachidonic acid. There was no clearcut relationship of these biochemical abnormalities to prolongation of bleeding time or to thrombotic and hemorrhagic symptoms. The defect was still present in 15 patients after treatment had returned the cell counts to the normal range. Normal levels of 5HT and adenine nucleotides were observed in 8 patients whose platelet counts were high after splenectomy for non-hematological reasons. These findings suggest that biochemical abnormalities are related to the presence in the bone marrow of abnormal clones, resulting in the production of defective platelets.
Collapse
Affiliation(s)
- F I Pareti
- The Hemophilia and Thrombosis Centre Angelo Bianchi Bonomi and Third Department of Medicine, University of Milano; Institute of Hematology “Lorenzo and Ariosto Seragnoli”, University of Bologna, Italy
| | - L Gugliotta
- The Hemophilia and Thrombosis Centre Angelo Bianchi Bonomi and Third Department of Medicine, University of Milano; Institute of Hematology “Lorenzo and Ariosto Seragnoli”, University of Bologna, Italy
| | - L Mannucci
- The Hemophilia and Thrombosis Centre Angelo Bianchi Bonomi and Third Department of Medicine, University of Milano; Institute of Hematology “Lorenzo and Ariosto Seragnoli”, University of Bologna, Italy
| | - A Guarini
- The Hemophilia and Thrombosis Centre Angelo Bianchi Bonomi and Third Department of Medicine, University of Milano; Institute of Hematology “Lorenzo and Ariosto Seragnoli”, University of Bologna, Italy
| | - P M Mannucci
- The Hemophilia and Thrombosis Centre Angelo Bianchi Bonomi and Third Department of Medicine, University of Milano; Institute of Hematology “Lorenzo and Ariosto Seragnoli”, University of Bologna, Italy
| |
Collapse
|
13
|
Maragliano R, Fanale D, Incorvaia L, Caruso S, Barraco N, Badalamenti G, Rizzo S, Calò V, Perez A, Listì A, Galvano A, Passiglia F, Guarini A, Bronte E, Insalaco L, Massihnia D, Castellana L, Di Piazza F, Bazan V, Russo A. Can the salivary microRNA expression profile help to identify novel biomarkers for oral squamous cell carcinoma detection? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx430.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Massihnia D, Funel N, Leon L, Castiglia M, Perez A, Barraco N, Listì A, Galvano A, Passiglia F, Guarini A, Calò V, Rizzo S, Castellana L, Giovannetti E, Russo A. Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
15
|
Giudice ID, Rigolin GM, Raponi S, Cafforio L, Ilari C, Wang J, Bordyuh M, Piciocchi A, Marinelli M, Nanni M, Tavolaro S, Filetti M, Bardi A, Tammiso E, Volta E, Negrini M, Saccenti E, Mauro FR, Rossi D, Gaidano G, Guarini A, Rabadan R, Cuneo A, Foà R. Refined karyotype-based prognostic stratification of chronic lymphocytic leukemia with a low- and very-low-risk genetic profile. Leukemia 2017; 32:543-546. [PMID: 28924243 DOI: 10.1038/leu.2017.292] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- I Del Giudice
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - G M Rigolin
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - S Raponi
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - L Cafforio
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - C Ilari
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - J Wang
- Divisions of Life Science and Biomedical Engineering, Hong Kong University of Science and Technology, Hong Kong, China
| | - M Bordyuh
- Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA
| | - A Piciocchi
- GIMEMA Data Centre, GIMEMA Foundation, Rome, Italy
| | - M Marinelli
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - M Nanni
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - S Tavolaro
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - M Filetti
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - A Bardi
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - E Tammiso
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - E Volta
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - M Negrini
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - E Saccenti
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - F R Mauro
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| | - D Rossi
- Hematology, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland
| | - G Gaidano
- Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | - A Guarini
- Department of Molecular Medicine, Sapienza University, Rome, Italy
| | - R Rabadan
- Department of Biomedical Informatics, Center for Computational Biology and Bioinformatics, Columbia University, New York, NY, USA
| | - A Cuneo
- Hematology Section, Azienda Ospedaliera Universitaria Arcispedale S. Anna, University of Ferrara, Ferrara, Italy
| | - R Foà
- Hematology, Department of Cellular Biotechnologies and Hematology, Policlinico Umberto I, Sapienza University, Rome, Italy
| |
Collapse
|
16
|
Incorvaia L, Badalamenti G, Musso E, de luca I, Casarin A, Assanto G, Galvano A, Passiglia F, Barraco N, Vincenzi B, Grignani G, Pantaleo M, Gatto L, Rizzo S, Fanale D, Castiglia M, Guarini A, Russo A. Predictive factors of response to Sunitinib in metastatic Gastrointestinal Stromal Tumors (mGISTs): A retrospective analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx387.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Pulsoni A, Della Starza I, Cappelli L, Tosti M, Annechini G, Cavalli M, De Novi L, D'Elia G, Grapulin L, Guarini A, Del Giudice I, Foa' R. MINIMAL RESIDUAL DISEASE (MRD) IN EARLY STAGE FOLLICULAR LYMPHOMA CAN PREDICT PROGNOSIS AND DRIVE RITUXIMAB TREATMENT AFTER RADIOTHERAPY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- A. Pulsoni
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - I. Della Starza
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - L.V. Cappelli
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - M.E. Tosti
- National Center for Global Health; National Institute of Health; Rome Italy
| | - G. Annechini
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - M. Cavalli
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - L.A. De Novi
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - G.M. D'Elia
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - L. Grapulin
- Radiologic Science; Sapienza University; Rome Italy
| | - A. Guarini
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - I. Del Giudice
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - R. Foa'
- Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| |
Collapse
|
18
|
Ciavarella S, Laurenzana A, De Summa S, Pilato B, Chillà A, Lacalamita R, Minoia C, Margheri F, Iacobazzi A, Rana A, Merchionne F, Fibbi G, Del Rosso M, Guarini A, Tommasi S, Serratì S. u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression. BMC Cancer 2017; 17:215. [PMID: 28340565 PMCID: PMC5366111 DOI: 10.1186/s12885-017-3183-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2016] [Accepted: 03/09/2017] [Indexed: 01/07/2023] Open
Abstract
Background Multiple Myeloma (MM) is a B-cell malignancy in which clonal plasma cells progressively expand within the bone marrow (BM) as effect of complex interactions with extracellular matrix and a number of microenvironmental cells. Among these, cancer-associated fibroblasts (CAF) mediate crucial reciprocal signals with MM cells and are associated to aggressive disease and poor prognosis. A large body of evidence emphasizes the role of the urokinase plasminogen activator (u-PA) and its receptor u-PAR in potentiating the invasion capacity of tumor plasma cells, but little is known about their role in the biology of MM CAF. In this study, we investigated the u-PA/u-PAR axis in MM-associated fibroblasts and explore additional mechanisms of tumor/stroma interplay in MM progression. Methods CAF were purified from total BM stromal fraction of 64 patients including monoclonal gammopathy of undetermined significance, asymptomatic and symptomatic MM, as well as MM in post-treatment remission. Flow cytometry, Real Time PCR and immunofluorescence were performed to investigate the u-PA/u-PAR system in relation to the level of activation of CAF at different stages of the disease. Moreover, proliferation and invasion assays coupled with silencing experiments were used to prove, at functional level, the function of u-PAR in CAF. Results We found higher activation level, along with increased expression of pro-invasive molecules, including u-PA, u-PAR and metalloproteinases, in CAF from patients with symptomatic MM compared to the others stages of the disease. Consistently, CAF from active MM as well as U266 cell line under the influence of medium conditioned by active MM CAF, display higher proliferative rate and invasion potential, which were significantly restrained by u-PAR gene expression inhibition. Conclusions Our data suggest that the stimulation of u-PA/u-PAR system contributes to the activated phenotype and function of CAF during MM progression, providing a biological rationale for future targeted therapies against MM.
Collapse
Affiliation(s)
- S Ciavarella
- National Cancer Research Centre IRCCS "Giovanni Paolo II", 70124, Bari, Italy
| | - A Laurenzana
- Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Florence, Italy
| | - S De Summa
- Molecular Genetics Laboratory, National Cancer Research Centre, IRCCS "Giovanni Paolo II", 70124, Bari, Italy
| | - B Pilato
- Molecular Genetics Laboratory, National Cancer Research Centre, IRCCS "Giovanni Paolo II", 70124, Bari, Italy
| | - A Chillà
- Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Florence, Italy
| | - R Lacalamita
- Molecular Genetics Laboratory, National Cancer Research Centre, IRCCS "Giovanni Paolo II", 70124, Bari, Italy
| | - C Minoia
- National Cancer Research Centre IRCCS "Giovanni Paolo II", 70124, Bari, Italy
| | - F Margheri
- Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Florence, Italy
| | - A Iacobazzi
- National Cancer Research Centre IRCCS "Giovanni Paolo II", 70124, Bari, Italy
| | - A Rana
- National Cancer Research Centre IRCCS "Giovanni Paolo II", 70124, Bari, Italy
| | - F Merchionne
- National Cancer Research Centre IRCCS "Giovanni Paolo II", 70124, Bari, Italy
| | - G Fibbi
- Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Florence, Italy
| | - M Del Rosso
- Department of Experimental and Clinical Biomedical Sciences, Section of Experimental Pathology and Oncology, University of Florence, Florence, Italy
| | - A Guarini
- National Cancer Research Centre IRCCS "Giovanni Paolo II", 70124, Bari, Italy
| | - S Tommasi
- Molecular Genetics Laboratory, National Cancer Research Centre, IRCCS "Giovanni Paolo II", 70124, Bari, Italy
| | - S Serratì
- Molecular Genetics Laboratory, National Cancer Research Centre, IRCCS "Giovanni Paolo II", 70124, Bari, Italy. .,Nanotecnology Laboratory, National Cancer Research Centre, IRCCS "Giovanni Paolo II", Bari, Italy.
| |
Collapse
|
19
|
Passiglia F, Galvano A, Rizzo S, Listì A, Barraco N, Maragliano R, Insalaco L, Bronte E, Alessi I, Guarini A, Terruso L, Castellana L, Perez A, Massihnia D, Di Piazza F, Calò V, Castiglia M, Bazan V, Russo A. The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
20
|
Mele G, Melpignano A, Quarta G, Palumbo G, Capalbo S, Falcone A, Cascavilla N, Palazzo G, Mazza P, Iannitto E, Curci P, Rizzi R, Specchia G, Rossini B, Pavone V, Ria R, Vacca A, Buquicchio C, Tarantini G, Minoia C, Guarini A, Ditonno P, Polimeno G, Reddiconto G, Di Renzo N. “Real world” outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: Extended follow-up of a retrospective multicenter study by the “rete ematologica pugliese”. Leuk Res 2015; 39:279-83. [DOI: 10.1016/j.leukres.2014.12.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Revised: 12/01/2014] [Accepted: 12/14/2014] [Indexed: 11/29/2022]
|
21
|
Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, Gentile M, Morabito F, Coscia M, Bellò M, Sacchetti GM, Rossi D, Laurenti L, Autore F, Campanelli M, Trastulli F, Nicolai E, Riminucci M, Gaidano G, Guarini A, Gallamini A, Foà R. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia 2015; 29:1360-5. [DOI: 10.1038/leu.2015.21] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2014] [Revised: 10/25/2014] [Accepted: 12/10/2014] [Indexed: 11/09/2022]
|
22
|
Santoro C, Di Mauro R, Baldacci E, De Angelis F, Abbruzzese R, Barone F, Bochicchio RA, Ferrara G, Guarini A, Foà R, Mazzucconi MG. Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. Haemophilia 2015; 21:496-501. [DOI: 10.1111/hae.12628] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/08/2014] [Indexed: 01/08/2023]
Affiliation(s)
- C. Santoro
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - R. Di Mauro
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - E. Baldacci
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - F. De Angelis
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - R. Abbruzzese
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - F. Barone
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - R. A. Bochicchio
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - G. Ferrara
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - A. Guarini
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - R. Foà
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| | - M. G. Mazzucconi
- Division of Hematology; Department of Cellular Biotechnologies and Hematology; “Sapienza” University of Rome; Rome Italy
| |
Collapse
|
23
|
Guarini A, Riera L, Reato G, Carbone A, Cignetti A, Tos A, Lanfrancone L, Melani C, Paul R, Forni G, Foa R. Human lung carcinoma cells engineered to release IL2, IL7, GM-CSF and TNF alpha. Int J Oncol 2012; 8:765-72. [PMID: 21544424 DOI: 10.3892/ijo.8.4.765] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
A human lung adenocarcinoma cell line (LC89) was transduced with the IL2, IL7, GM-CSF and TNF alpha genes by retroviral vector mediated infection. This induced the constitutive and stable release of all cytokines. No difference or modulation was found in the parental and gene transduced LC89 cells with regard to cytokine receptor expression, in vitro cell growth and proliferation, nor in cell surface expression of different adhesion molecules. Following injection into immunosuppressed nu/nu mice, IL2 gene transduced LC89 cells lost their tumorigenic potential. LC89 cells engineered to release IL7 and TNF alpha grew in nu/nu mice, but in 40% of the animals tumor regression was observed. GM-CSF gene transduced LC89 cells showed a tumorigenic capacity identical to that of the parental clone. The levels of TGF beta(1) released by IL2, IL7 and GM-CSF gene transduced LC89 cells were markedly reduced compared to those of the parental and TNF alpha gene transduced cells. The results of this study support the concept that human lung cancer cells engineered with different cytokine genes maintain their intrinsic morphologic and proliferative features, while their tumorigenic and immunosuppressive capacities can be profoundly down-modulated. Both these effects are optimally achieved following insertion of the IL2 gene, suggesting that vaccination protocols with IL2 gene transduced tumor cells may be considered for the management of human lung cancer.
Collapse
Affiliation(s)
- A Guarini
- UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,SEZ CLIN,I-10126 TURIN,ITALY. IST EUROPEO ONCOL,DIPARTIMENTO ONCOL SPERIMENTALE,MILAN,ITALY. IST NAZL TUMORI,DIV ONCOL SPERIMENTALE,I-20133 MILAN,ITALY. TARGETED GENET CORP,SEATTLE,WA. UNIV TURIN,CTR IMMUNOGENET & ONCOL SPERIMENTALE,CNR,TURIN,ITALY
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Rossi D, Rasi S, Spina V, Bruscaggin A, Monti S, Cresta S, Famà R, Deambrogi C, Greco M, Fangazio M, Ciardullo C, Piranda D, Casaluci GM, Messina M, Giudice ID, Chiaretti S, Marinelli M, Guarini A, Foà R, Gaidano G. The genome of chemorefractory chronic lymphocytic leukemia reveals frequent mutations of NOTCH1 and SF3B1. Leuk Suppl 2012; 1:S26-8. [PMID: 27175239 DOI: 10.1038/leusup.2012.16] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Next-generation whole-exome sequencing has revealed two novel genes, namely NOTCH1 and SF3B1, whose mutations predict poor outcome and preferentially associate with chemorefractory chronic lymphocytic leukemia (CLL). Analysis of 539 CLL cases documents that NOTCH1 mutations i) represent one of the most frequent cancer gene mutations involved at presentation; ii) cluster with cases harboring trisomy 12 and tend to be mutually exclusive with TP53 disruption among genetic subgroups; iii) identify high-risk patients showing poor survival similar to that associated with TP53 abnormalities; and iv) exert a prognostic role independent of widely accepted clinical and genetic risk factors. Mutations of SF3B1, a splicing factor that is a critical component of the spliceosome, recurrently associate with fludarabine-refractory CLL, occur at a low rate at CLL presentation and have a minor role in Richter transformation, corroborating the notion that CLL histological shift is molecularly distinct from chemorefractory progression without the Richter transformation.
Collapse
Affiliation(s)
- D Rossi
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - S Rasi
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - V Spina
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - A Bruscaggin
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - S Monti
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - S Cresta
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - R Famà
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - C Deambrogi
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - M Greco
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - M Fangazio
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - C Ciardullo
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - D Piranda
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - G M Casaluci
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| | - M Messina
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - I D Giudice
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - S Chiaretti
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - M Marinelli
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - A Guarini
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University , Rome, Italy
| | - R Foà
- Division of Hematology, Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy; Fondazione Eleonora Lorillard Spencer Cenci, Sapienza University, Rome, Italy
| | - G Gaidano
- Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont , Novara, Italy
| |
Collapse
|
25
|
Guarini A, Minoia C, Giannoccaro M, Rana A, Iacobazzi A, Lapietra A, Raimondi A, Silvestris N, Gadaleta CD, Ranieri G. mTOR as a target of everolimus in refractory/relapsed Hodgkin lymphoma. Curr Med Chem 2012; 19:945-54. [PMID: 22214465 DOI: 10.2174/092986712799320727] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2011] [Revised: 11/16/2011] [Accepted: 11/18/2011] [Indexed: 11/22/2022]
Abstract
Despite impressive treatment advances, few options for refractory or relapsed Hodgkin Lymphoma (HL) are available and there is a need for new compounds development. A number of promising agents with multiple mechanisms of action are under investigation. Microenvironment and neoangiogenesis are acquiring a rising relevance in the pathophysiology and progression of HL. Everolimus (RAD001) is an oral antineoplastic agent derived from rapamycin, a macrocyclic lactone antibiotic, targeting the mammalian target of rapamycin (mTOR). Although the importance of mTOR signaling in the deregulated cell growth of human neoplastic cells has been recognized, this pathway is also emerging as a key regulator of the tumor response to hypoxia, as well as endothelial and stromal cells function, thereby regulating neoangiogenesis. Furthermore, mTOR plays an important role in anticancer drug resistance. The actions of everolimus within the mTOR pathway in HL result in decreased protein synthesis and cell cycle arrest, as well as in decreased angiogenesis. Everolimus has shown preliminary evidence of efficacy as a single-agent in heavily pretreated relapsed/refractory HL, with an overall fair safety profile. The purpose of this review is to discuss the employment of everolimus as an antiproliferative and antiangiogenic agent in HL and to report the critical role of the mTOR pathway and angiogenesis in this malignancy.
Collapse
Affiliation(s)
- A Guarini
- Haematology Unit, National Cancer Centre "Giovanni Paolo II" Bari, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Berardi S, Caivano A, Ria R, Nico B, Savino R, Terracciano R, De Tullio G, Ferrucci A, De Luisi A, Moschetta M, Mangialardi G, Catacchio I, Basile A, Guarini A, Zito A, Ditonno P, Musto P, Dammacco F, Ribatti D, Vacca A. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. Oncogene 2011; 31:2258-69. [PMID: 21963844 DOI: 10.1038/onc.2011.412] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Bone marrow (BM) angiogenesis has an important role in the initiation and progression of multiple myeloma (MM). We looked at novel mechanisms of vessel formation in patients with MM through a comparative proteomic analysis between BM endothelial cells (ECs) of patients with active MM (MMECs) and ECs of patients with monoclonal gammopathy of undetermined significance (MGECs) and of subjects with benign anemia (normal ECs). Four proteins were found overexpressed in MMECs: filamin A, vimentin, α-crystallin B and 14-3-3ζ/δ protein, not yet linked to overangiogenic phenotype. These proteins gave a typical distribution in the BM of MM patients and in MMECs versus MGECs, plausibly according to a different functional state. Their expression was enhanced by vascular endothelial growth factor, fibroblast growth factor 2, hepatocyte growth factor and MM plasma cell conditioned medium in step with enhancement of MMEC angiogenesis. Their silencing RNA knockdown affected critical MMEC angiogenesis-related functions, such as spreading, migration and tubular morphogenesis. A gradual stabilization of 14-3-3ζ/δ protein was observed, with transition from normal ECs to MGECs and MMECs that may be a critical step for the angiogenic switch in MMECs and maintenance of the cell overangiogenic phenotype. These proteins were substantially impacted by anti-MM drugs, such as bortezomib, lenalidomide and panobinostat. Results suggest that these four proteins could be new targets for the antiangiogenic management of MM patients.
Collapse
Affiliation(s)
- S Berardi
- Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Mauro FR, Ciolli S, Di Raimondo F, Del Poeta G, Forconi F, Cuneo A, Cortellezzi A, Nobile F, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Orsucci L, Mura MA, Alietti A, Runggaldier EJ, Gamba E, Guarini A, Foa R. A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: Results of the induction phase. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.6629] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Sansavini A, Savini S, Guarini A, Broccoli S, Alessandroni R, Faldella G. The effect of gestational age on developmental outcomes: a longitudinal study in the first 2 years of life. Child Care Health Dev 2011; 37:26-36. [PMID: 20666779 DOI: 10.1111/j.1365-2214.2010.01143.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Extremely low and very low gestational age (ELGA and VLGA) constitutes a risk factor for development even in absence of cerebral damage, as an immature central nervous system is exposed to invasive and inadequate stimulation. We tested the hypothesis that GA impacts developmental outcomes and trajectories of preterms without major cerebral damage in the first 2 years of life, expecting poorer developmental outcomes and higher rate of impairment with the decreasing of GA. We also evaluated whether GA, together with developmental outcomes in the first year of life, was related to developmental outcomes at 24 months. METHODS Eighty-eight infants, divided into three GA groups (ELGA: ≤28 weeks; VLGA: 29-32 weeks; full term: >37 weeks) were assessed longitudinally at 6, 12, 18 and 24 months using the Griffiths Mental Development Scales. RESULTS Use of a repeated measure multivariate analysis of variance resulted in several significant findings. GA was associated with the developmental quotient (DQ) scores (P= 0.006); and locomotor (P < 0.001), eye and hand co-ordination (P= 0.016) and performance (P= 0.040) sub-scale quotient (SQ) scores; age of evaluation was also associated with DQ scores (P= 0.002), and locomotor (P < 0.001) and performance (P < 0.001) SQ scores. In particular, ELGAs exhibited lower DQ and SQ scores compared with the VLGA and full-term groups; some ELGAs showed mild, moderate or severe cognitive impairments, while few VLGAs mild impairments. Linear regression analysis showed that GA (P= 0.034) and 12-month developmental outcome (P < 0.001) were related to 24-month developmental outcome. CONCLUSIONS Different developmental trajectories emerged in relation to GA, with poorer developmental outcomes and higher rates of impairment in ELGAs and few mild impairments in VLGAs. The relevance of taking into account both GA and repeated assessments in the first 2 years of life was shown.
Collapse
Affiliation(s)
- A Sansavini
- Department of Psychology, University of Bologna, viale Berti Pichat 5, Bologna, Italy.
| | | | | | | | | | | |
Collapse
|
29
|
De Luisi A, Ferrucci A, Di Pietro G, Berardi S, Basile A, Ria R, Ribatti D, Coluccia A, Maffia M, Ranieri G, Paradiso A, Guarini A, Vacca A. 38 ANTIANGIOGENIC PROPERTIES OF IMMUNOMODULATORY DRUG LENALIDOMIDE IN ENDOTHELIAL CELLS OF PATIENTS WITH ACTIVE MULTIPLE MYELOMA. Cancer Treat Rev 2010. [DOI: 10.1016/s0305-7372(10)70064-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Oliva S, Fioretti A, Jacobazzi A, Rana A, Lapietra A, Giotta F, Guarini A, Colucci G. 1 ECHOCARDIOGRAPHIC MONITORING DURING ANTHRACYCLINE ADMINISTRATION IN PATIENTS WITH HODGKIN'S AND NON-HODGKIN'S LYMPHOMA: THE TEI-INDEX EVALUATION. Cancer Treat Rev 2010. [DOI: 10.1016/s0305-7372(10)70027-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
31
|
Minoia C, Zito F, Quero C, Rana A, Iacobazzi A, Lapietra A, Giannoccaro M, Daniele G, Ferrucci A, Guarini A. 77 ANGIOGENESIS IN INDOLENT NON-HODGKIN'S LYMPHOMA (NHL). Cancer Treat Rev 2010. [DOI: 10.1016/s0305-7372(10)70103-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Fioretti A, Oliva S, Giotta F, Iacobazzi A, Guarini A, Colucci G. Echocardiography monitoring in patients with Hodgkin's and non-Hodgkin's lymphoma: The Tei-Index evaluation. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18563] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
33
|
Foa R, Tos AG, Francia di Celle P, Carbone A, Marchis D, Vischia F, Cignetti A, Guarini A. Cytokines in B-Cell Chronic Lymphocytic Leukemia. Leuk Lymphoma 2009; 5 Suppl 1:7-11. [DOI: 10.3109/10428199109103372] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
34
|
Foa R, Vischia F, Pini M, Lauria F, Guarini A. Use of the MTT Chemosensitivity Assay in B-Cell Chronic Lymphocytic Leukemia. Leuk Lymphoma 2009; 5 Suppl 1:71-5. [DOI: 10.3109/10428199109103382] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
35
|
|
36
|
Breccia M, Latagliata R, Carmosino I, Cannella L, Diverio D, Guarini A, De Propris MS, Petti MC, Avvisati G, Cimino G, Mandelli F, Lo-Coco F. Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. Haematologica 2008; 93:1918-20. [DOI: 10.3324/haematol.13510] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
37
|
Mauro FR, Coluzzi S, Del Giudice I, Armiento D, De Propris MS, Starza ID, De Nicolo' MC, Guarini A, Girelli G, Foa' R. Evidence of a sub-clinical lymphoproliferative disease in patients with ‘idiopathic‘ autoimmune hemolytic anemia. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.7074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
38
|
Santoro C, Rago A, Biondo F, De Propris MS, De Vellis A, Guarini A, Pignoloni P, Mazzucconi MG. Efficacy of rituximab treatment in postpartum acquired haemophilia A. Haemophilia 2007; 14:147-9. [PMID: 17961170 DOI: 10.1111/j.1365-2516.2007.01587.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
39
|
Breccia M, Avvisati G, Latagliata R, Carmosino I, Guarini A, De Propris MS, Gentilini F, Petti MC, Cimino G, Mandelli F, Lo-Coco F. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia 2006; 21:79-83. [PMID: 16932337 DOI: 10.1038/sj.leu.2404377] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Although the occurrence of thrombosis in acute promyelocytic leukemia (APL) has been reported during retinoic acid treatment, no studies carried out in large clinical cohorts have specifically addressed this issue. We analyzed 124 APL patients treated with the all-trans retinoic acid and idarubicin protocol and compared clinico-biologic characteristics of 11 patients who developed thrombosis with those of 113 patients who had no thrombosis. In seven patients, the events were recorded during induction, whereas in four patients deep vein thrombosis occurred in the post-induction phase. Comparison of clinico-biological characteristics of patients with and without thrombosis revealed in the former group higher median white blood cell (WBC) count (17 x 10(9)/l, range 1.2-56, P=0.002), prevalence of the bcr3 transcript type (72 vs 48%, P=0.01), of FLT3-ITD (64 vs 28%, P=0.02), CD2 (P=0.0001) and CD15 (P=0.01) expression. No correlation was found with sex, age, French-American-British subtype, all-trans-retinoic acid syndrome or with thrombophilic state that was investigated in 5/11 patients. Our findings suggest that, in APL patients consistent biologic features of leukemia cells may predict increased risk of developing thrombosis.
Collapse
MESH Headings
- Adult
- Aged
- Antibiotics, Antineoplastic/administration & dosage
- Antibiotics, Antineoplastic/adverse effects
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/adverse effects
- CD2 Antigens
- Female
- Humans
- Idarubicin/administration & dosage
- Idarubicin/adverse effects
- Leukemia, Promyelocytic, Acute/blood
- Leukemia, Promyelocytic, Acute/drug therapy
- Leukemia, Promyelocytic, Acute/genetics
- Leukemia, Promyelocytic, Acute/immunology
- Leukocyte Count
- Lewis X Antigen
- Male
- Middle Aged
- Mutation
- Predictive Value of Tests
- Risk Factors
- Tandem Repeat Sequences/genetics
- Thrombosis/chemically induced
- Thrombosis/genetics
- Thrombosis/immunology
- Tretinoin/administration & dosage
- Tretinoin/adverse effects
- fms-Like Tyrosine Kinase 3/genetics
Collapse
Affiliation(s)
- M Breccia
- Department of Cellular Biotechnology and Hematology, University La Sapienza, Rome, Italy.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A, Liso V, Perrone T, Liso A. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37:719-24. [PMID: 16518434 DOI: 10.1038/sj.bmt.1705298] [Citation(s) in RCA: 85] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Haemopoietic stem cell therapy is an increasingly adopted procedure in the treatment of patients with malignant lymphoma. In this retrospective analysis, we evaluated 262 patients, 57 (22%) with Hodgkin's and 205 (78%) with non-Hodgkin's lymphomas (NHL), and 665 harvesting procedures in order to assess the impact of poor mobilization on survival and to determine the factors that may be predictive of CD34(+) poor mobilization. The mobilization chemotherapy regimens consisted of high-dose cyclophosphamide in 92 patients (35.1%) and a high-dose cytarabine-containing regimen (DHAP in 87 patients -(33.2%), MAD in 83 (31.7%)). The incidence of poor mobilizers (<2 x 10(6) CD34(+) cells/kg) was 17.9% overall, with a 10% of very poor mobilizers (< or = 1 x 10(6)/kg). Refractory disease status and chemotherapeutic load (>3 regimens) before mobilization played a negative role and were associated with poor mobilization. Survival analysis of all harvested patients showed an overall survival at 3 years of 71% in good mobilizers vs 33% in poor mobilizers (P=0.002). The event-free survival at 3 years was 23% in poor mobilizers and 58% in good mobilizers (P=0.04). We conclude that in NHL patients, poor mobilization status is predictive of survival.
Collapse
Affiliation(s)
- V Pavone
- Hematology Department, University of Bari, Bari, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
41
|
Capello D, Guarini A, Berra E, Mauro FR, Rossi D, Ghia E, Cerri M, Logan J, Foà R, Gaidano G. Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia. Leukemia 2004; 18:1941-7. [PMID: 15483675 DOI: 10.1038/sj.leu.2403537] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Recognition of biased immunoglobulin variable (IgV) gene usage in B-cell chronic lymphocytic leukemia (B-CLL) may yield insight into leukemogenesis and may help to refine prognostic categories. We explored Ig variable heavy (VH) and light (VL) chain gene usage in highly stable and indolent B-CLL (n=25) who never required treatment over 10 or more years. We observed an unexpectedly high usage of mutated VH3-72 (6/25; 24.0%), a gene that was otherwise rare in B-CLL (7/805; 0.87%; P<0.01), including mutated cases (6/432; 1.39%; P<0.01) and was exceptional among indolent (1/230, 0.435%; P<0.01), and aggressive B-cell lymphomas (0/105; P<0.01). Three of six VH3-72 B-CLL cases utilized the same VL Vkappa4-1 gene. Two V(H)3-72 B-CLL cases had highly homologous VH complementarity determining regions 3 (CDR3s), encoding Cys-XXXX-Cys domains, and utilized Vkappa4-1 genes with homologous IgVL CDR3s. An identical threonine to isoleucine change at codon 84 of V(H)3-72 framework region 3 (FR3) recurred in four cases of highly stable VH3-72 B-CLL. This mutation is expected to cause a conformational change of FR3 proximal to CDR3 that might critically affect high-affinity antigen binding. B-cell receptors encoded by VH3-72 may identify a specific B-CLL group and be implicated in leukemogenesis through an antigen-driven expansion of B cells.
Collapse
MESH Headings
- Amino Acid Sequence
- Base Sequence
- Complementarity Determining Regions/chemistry
- Complementarity Determining Regions/genetics
- Gene Rearrangement
- Humans
- Immunoglobulin Heavy Chains/chemistry
- Immunoglobulin Heavy Chains/genetics
- Immunoglobulin Variable Region/chemistry
- Immunoglobulin Variable Region/genetics
- Immunoglobulin kappa-Chains/chemistry
- Immunoglobulin kappa-Chains/genetics
- Immunoglobulin lambda-Chains/chemistry
- Immunoglobulin lambda-Chains/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/genetics
- Leukemia, Lymphocytic, Chronic, B-Cell/metabolism
- Leukemia, Lymphocytic, Chronic, B-Cell/pathology
- Molecular Sequence Data
- Mutation
- Prognosis
- Protein Conformation
- Receptors, Antigen, B-Cell/chemistry
- Receptors, Antigen, B-Cell/genetics
- Receptors, Antigen, B-Cell/metabolism
- Sequence Homology, Amino Acid
- Sequence Homology, Nucleic Acid
Collapse
Affiliation(s)
- D Capello
- Hematology Unit, Department of Medical Sciences & IRCAD, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, Cignetti A, Cordone I, Montefusco E, Mandelli F, Foa R. Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression. Hematol J 2002; 1:7-14. [PMID: 11920164 DOI: 10.1038/sj.thj.6200004] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/22/1999] [Accepted: 09/17/1999] [Indexed: 11/09/2022]
Abstract
INTRODUCTION Interferon-alpha (IFN) plays a role in the management of different neoplasias, particularly those of hematological origin. The mechanisms of action of IFN are still poorly understood and the individual response is unpredictable. In the present study, the pattern of intracellular gene expression following in vitro and in vivo exposure of chronic myeloid leukemia (CML) cells to IFN was evaluated and correlated with the response to in vivo treatment with IFN. MATERIALS AND METHODS CML patients in different phases of the disease were studied. The pattern of expression of two IFN-inducible proteins involved in IFN-mediated biological activities, the p91 and p84 proteins (STAT1alpha and STAT1beta), components of the IFN-stimulated gene factor 3 (ISGF3) complex and the enzyme 2'-5' oligoadenylate synthetase (2'-5' OASE) were investigated by Western blot in peripheral blood mononuclear cells stimulated or not in vitro by IFN. RESULTS AND CONCLUSIONS In 6/9 patients evaluated before starting treatment, STAT1 was expressed either constitutively or after in vitro stimulation by IFN. In three cases, STAT1 remained negative even after in vitro activation. The pattern of protein expression correlated with the subsequent hematological response to prolonged in vivo IFN administration: the presence of STAT1 being associated with the clinical response to IFN and the absence and non-inducibility of STAT1 with resistance to IFN. This was further substantiated by studies carried out in ten patients analyzed at the time of a documented clinico-hematological response or resistance to the in vivo administration of IFN. Finally, in order to establish whether the pattern of response to IFN treatment could be predicted at diagnosis, cells cyropreserved at diagnosis from patients with a documented complete response, confirmed also by cytogenetic negativity, or resistance, were studied. While complete responders proved STAT1 positive, none of the four resistant cases ever expressed STAT1. The expression of 2'-5' OASE did not correlate with the clinical response to IFN. This study documents the pivotal role of STAT1 in the in vitro and in vivo responses of CML cells to IFN. The constitutive or induced presence or absence of STAT1 shows a predictive correlation with the response or resistance to treatment with IFN and could be utilized to identify, at diagnosis, resistant patients who may be spared an expensive and unnecessary prolonged IFN administration.
Collapse
Affiliation(s)
- S Landolfo
- Centro CNR di Immunogenetica ed Oncologia Sperimentale, University of Torino, Torino, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
|
44
|
Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, Liso V. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29:285-90. [PMID: 11896424 DOI: 10.1038/sj.bmt.1703364] [Citation(s) in RCA: 63] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2001] [Accepted: 10/04/2001] [Indexed: 11/08/2022]
Abstract
Our study analyzes the mobilization of hematopoietic stem cells after two chemotherapeutic regimens in non-Hodgkin's lymphoma (NHL) patients. The study included 72 patients with NHL (42 follicular and 30 large cells). The mean age was 37 years (range 17-60). Sixty-four patients (88.9%) had stage III-IV disease. Forty-eight patients (66.7%) had bone marrow involvement. Systemic B symptoms were present in 42 patients (58.3%). Mobilization chemotherapy regimens were randomly assigned as DHAP in 38 patients (52.7%) or cyclophosphamide (CPM) (5 g/m(2)) in 34 (47.2%) and the results of 132 procedures were analyzed. At the time of PBSC mobilization, 46 patients (63.9%) were considered to be responsive (complete remission, partial remission or sensitive relapse) and 26 (36.1%) not responsive (refractory relapse or refractory to therapy). Pre-apheresis CD34+ blood cell count and number of previous chemotherapy treatments were used to predict the total number of CD34+ cells in the apheresis product. The mobilizing regimens (CPM or DHAP) were similar in achieving the threshold CD34+ cell yield, for optimal engraftment. Since DHAP was very effective as salvage treatment, we suggest using DHAP as a mobilizing regimen in patients with active residual lymphoma at the time of stem cell collection.
Collapse
Affiliation(s)
- V Pavone
- Haematology, University of Bari, Medical School, Policlinico Bari, Italy
| | | | | | | | | | | | | |
Collapse
|
45
|
Torelli GF, Orsini E, Guarini A, Kell J, Foà R. Developmental approaches in immunological control of acute myelogenous leukaemia. Best Pract Res Clin Haematol 2001; 14:189-209. [PMID: 11355931 DOI: 10.1053/beha.2000.0123] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
After many years of hope and disillusionment, the possibility of utilizing immune-mediated approaches to control neoplastic clones has become a reality in various haematological malignancies. This is largely a consequence of the continuous advances in knowledge and the progressive development of more refined technologies that have led to a better understanding of the biology of the malignant cells and of the host immune system, to a more precise definition of disease entities and to the design of innovative therapeutic programmes. In this chapter, we will review different immunological strategies that have reached clinical practice in patients with acute myelogenous leukaemia (AML), the focus of this volume, and discuss pre-clinical developments that may in the near future translate into the design of new immunotherapeutic protocols for the management of AML. Treatment of AML with antibody directed therapy will also be discussed.
Collapse
Affiliation(s)
- G F Torelli
- Dipartimento di Biotecnologie Cellulari ed Ematologia, University 'La Sapienza', Via Benevento 6, Rome, 00161, Italy
| | | | | | | | | |
Collapse
|
46
|
Guarini A, Breccia M, Montefusco E, Petti MC, Zepparoni A, Vitale A, Foa R. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission. Br J Haematol 2001; 113:136-42. [PMID: 11328293 DOI: 10.1046/j.1365-2141.2001.02724.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The role of the host immune compartment in the control of chronic myeloid leukaemia (CML) has been suggested by numerous biological and clinical evidence. In the present study, the phenotypic and functional machinery of both T and cytotoxic lymphocytes was evaluated in a series of CML patients in complete haematological, and frequently also in cytogenetic, remission after treatment with interferon (IFN) alpha or hydroxyurea, and compared with the profile observed in patients at diagnosis and in normal controls. In particular, the lymphocyte subset distribution, the cytotoxic activity and the intracellular production of tumour necrosis factor (TNF)alpha and IFN gamma by CD4(+), CD8(+) and CD56(+) cells were investigated. CML patients in complete haematological remission showed a normalized CD4/CD8 T-cell subset distribution, as well as a restored spontaneous and interleukin 2 (IL-2) induced cytotoxic function compared with the pattern observed at diagnosis. This was associated with a significantly increased proportion of activated CD4(+) lymphocytes (CD25(+)). TNF alpha and IFN gamma production by CD4(+), CD8(+) and CD56(+) lymphocytes was significantly enhanced compared with that of patients at diagnosis. However, the values were lower than those of normal controls. These results indicate that, in contrast to the observations at presentation, CML patients, at the time of the best possible response to treatment, show a normalized T-cell subset distribution associated with an activated CD4 T-cell compartment and a restored cytotoxic activity. In addition, they also show a markedly increased intracellular cytokine production by the lymphoid populations that play an important role in the process of specific tumour recognition. The design of therapeutic strategies aimed at stimulating the host immune compartment finds a further rationale for CML patients responsive to treatment with both IFN alpha and hydroxyurea.
Collapse
Affiliation(s)
- A Guarini
- Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
In addition to the extensive work that has been conducted in order to understand better the biological features of the leukemic population in B-cell chronic lymphocytic leukemia (CLL), over the years considerable interest has been directed towards other related studies that may have important implications for the accumulation of the leukemic clone and for the immunoparesis typical of this disease. In the present review article, we discuss some of these areas of investigation and, in particular, we focus on: (1) the multiple abnormalities recorded within the T and cytotoxic compartment of patients with CLL; (2) cytokine loops occurring in this disease, with particular emphasis on the cytokines that appear to play a more critical role; and (3) the cell-to-cell cross talk that may be actively operational in CLL. These findings will be discussed in relation with the possible implications that each of them have in the expansion and clinical behavior of a disease that is increasingly proving its heterogeneity.
Collapse
Affiliation(s)
- E Orsini
- Dipartimento di Biotecnologie Cellulari ed Ematologia, University La Sapienza, Via Benevento 6, 00161 Rome
| | | | | |
Collapse
|
48
|
Cignetti A, Guarini A, Gillio Tos A, Reato G, Foa R. Interleukin-2 gene-transduced human leukemic cells induce major histocompatibility complex-restricted and -unrestricted anti-leukemic effectors in mixed lymphocyte-tumor cultures. Cancer Gene Ther 2000; 7:167-76. [PMID: 10770624 DOI: 10.1038/sj.cgt.7700107] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
To explore the feasibility of designing vaccination protocols in acute leukemia patients with cytokine gene-transduced leukemic cells, we studied in vitro the growth potential of human leukemic cells transduced with the interleukin-2 (IL-2), IL-7, or IL-7 plus IL-2 genes, as well as the capacity of generating both autologous and allogeneic cytotoxic lymphocytes directed against the parental cells. A lymphoblastic T-cell line, ST4, obtained from a patient in long-lasting complete remission, was retrovirally engineered with the IL-2, IL-7, and IL-7 plus IL-2 genes; in addition, clones releasing different amounts of the cytokines were obtained by limiting dilution. Mixed lymphocyte-tumor cultures (MLTCs) were set up with parental or transduced leukemic cells as stimulators and with autologous or allogeneic lymphocytes as responders. When nonirradiated ST4 parental cells or clones producing <50 international units (IU)/mL/10(6) cells/72 hours of IL-2 were used as stimulators, leukemic overgrowth was observed in MLTCs within 16 days of culture. When clones producing >80 IU/mL/10(6) cells/72 hours of IL-2 were used as stimulators, the proliferation of leukemic cells was blocked and the transduced leukemic cells were completely cleared from the cultures by day 16; repeated restimulations with IL-2-producing leukemic cells were required to sustain long-term lymphocyte survival. On the contrary, when IL-7- or IL-7-IL-2-producing cells were used as stimulators, only a delay in leukemic cell overgrowth was observed, and lymphocytes were completely cleared from the cultures after day 60. IL-7 production by the different clones ranged between 11 and 36 ng/mL/10(6) cells/72 hours, whereas the highest IL-2-producing IL-7-IL-2 clone released 50 IU/mL/10(6) cells/72 hours of IL-2. When the stimulator efficacy of the highest IL-2-producing clone (ST4/IL-2#A7) was compared with that of exogenous IL-2 plus parental cells, a 7-fold higher amount of exogenous IL-2 was required to achieve the same results obtained with IL-2-producing leukemic cells. Autologous and allogeneic long-term MLTCs (up to 35 days) with ST4/IL-2#A7 as the stimulator were capable of generating cytotoxic effectors equally endowed with both major histocompatibility complex (MHC) class I-unrestricted and -restricted activity against parental ST4 cells. By day 18 of both autologous and allogeneic cultures, a substantial proportion of CD56+ cells was consistently recorded; this was coupled to a predominantly MHC-unrestricted cytotoxic activity directed against parental ST4 cells. CD56+ cells decreased considerably at the end of the different MLTCs, together with the unrestricted cytotoxic activity. At this time, >50% of the cells were CD8+, and 55% of the activity could be blocked by an anti-MHC class I monoclonal antibody. The results of this study demonstrate that IL-2 gene-transduced human acute leukemia cells cocultured with both autologous and allogeneic lymphocytes are capable of inducing a strong MHC-unrestricted anti-leukemic activity and subsequently "educating" MHC class I-restricted anti-leukemic effectors. The evidence that the immunogenic potential of human leukemic blasts can be boosted after transfer of the IL-2 gene suggests that the possibility of using leukemic cells engineered to release IL-2 as a therapeutic vaccine needs to be explored further.
Collapse
MESH Headings
- Cancer Vaccines/immunology
- Cancer Vaccines/pharmacology
- Cell Division/genetics
- Cell Division/immunology
- Cell Transformation, Neoplastic/genetics
- Cell Transformation, Neoplastic/immunology
- Cytotoxicity, Immunologic/genetics
- Gene Transfer Techniques
- Genetic Therapy
- Humans
- Interleukin-2/genetics
- Interleukin-2/therapeutic use
- K562 Cells
- Leukemia, T-Cell/genetics
- Leukemia, T-Cell/immunology
- Leukemia, T-Cell/pathology
- Leukemia, T-Cell/therapy
- Lymphocyte Culture Test, Mixed
- Major Histocompatibility Complex/genetics
- Major Histocompatibility Complex/immunology
- Transforming Growth Factor beta/biosynthesis
- Tumor Cells, Cultured
- Vaccines, DNA/immunology
- Vaccines, DNA/pharmacology
Collapse
Affiliation(s)
- A Cignetti
- Dipartimento di Scienze Biomediche ed Oncologia Umana, University of Torino, Italy.
| | | | | | | | | |
Collapse
|
49
|
Landolfo S, Guarini A, Riera L, Gariglio M, Gribaudo G, Cignetti A, Cordone I, Montefusco E, Mandelli F, Foa R. Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression. Hematol J 2000. [PMID: 11920164 DOI: 10.1038/sj/thj/6200004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/15/2023]
Abstract
INTRODUCTION Interferon-alpha (IFN) plays a role in the management of different neoplasias, particularly those of hematological origin. The mechanisms of action of IFN are still poorly understood and the individual response is unpredictable. In the present study, the pattern of intracellular gene expression following in vitro and in vivo exposure of chronic myeloid leukemia (CML) cells to IFN was evaluated and correlated with the response to in vivo treatment with IFN. MATERIALS AND METHODS CML patients in different phases of the disease were studied. The pattern of expression of two IFN-inducible proteins involved in IFN-mediated biological activities, the p91 and p84 proteins (STAT1alpha and STAT1beta), components of the IFN-stimulated gene factor 3 (ISGF3) complex and the enzyme 2'-5' oligoadenylate synthetase (2'-5' OASE) were investigated by Western blot in peripheral blood mononuclear cells stimulated or not in vitro by IFN. RESULTS AND CONCLUSIONS In 6/9 patients evaluated before starting treatment, STAT1 was expressed either constitutively or after in vitro stimulation by IFN. In three cases, STAT1 remained negative even after in vitro activation. The pattern of protein expression correlated with the subsequent hematological response to prolonged in vivo IFN administration: the presence of STAT1 being associated with the clinical response to IFN and the absence and non-inducibility of STAT1 with resistance to IFN. This was further substantiated by studies carried out in ten patients analyzed at the time of a documented clinico-hematological response or resistance to the in vivo administration of IFN. Finally, in order to establish whether the pattern of response to IFN treatment could be predicted at diagnosis, cells cyropreserved at diagnosis from patients with a documented complete response, confirmed also by cytogenetic negativity, or resistance, were studied. While complete responders proved STAT1 positive, none of the four resistant cases ever expressed STAT1. The expression of 2'-5' OASE did not correlate with the clinical response to IFN. This study documents the pivotal role of STAT1 in the in vitro and in vivo responses of CML cells to IFN. The constitutive or induced presence or absence of STAT1 shows a predictive correlation with the response or resistance to treatment with IFN and could be utilized to identify, at diagnosis, resistant patients who may be spared an expensive and unnecessary prolonged IFN administration.
Collapse
Affiliation(s)
- S Landolfo
- Centro CNR di Immunogenetica ed Oncologia Sperimentale, University of Torino, Torino, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Abstract
The genital tract as a primary site of malignant lymphoma in women is extremely rare. This report concerns a 64 year old patient with a primary vaginal non-Hodgkin lymphoma (large cell B lineage according to the REAL classification--centroblastic type according to the Kiel classification--"G" according Working Formulation) with an unusual clinical presentation--pelvic discomfort accompanied by frequent ureteral-like colic. Due to gynecological onset symptoms and the rarity of this extranodal primary site misinterpretation of a primary vaginal lymphoma as a benign inflammatory disease or endometriosis may occur. We emphasize the importance of their recognition and also the differential diagnosis of cervical lymphoma from other neoplastic and non-neoplastic lesions.
Collapse
Affiliation(s)
- A Guarini
- Haematology Department, University of Bari, Italy.
| | | | | | | | | | | | | |
Collapse
|